Understanding the Relationship Between Corneal Nerve Function and the Ocular Surface (Archived CME Webcast)

This educational activity has expired. You will not be able to claim credit for this activity.

Activity Description and Purpose

Corneal nerve dysfunction is the underlying cause of neurotrophic keratitis and has an etiologic role in the pathogenesis of dry eye disease and its symptoms. Knowledge of the mechanisms has implications for establishing a diagnosis in patients with ocular surface disease and using neuroregenerative therapy. This educational activity is based on the proceedings of a live CME/CE symposium that took place on Monday, May 2, 2022. The desired results of this activity are to increase understanding of the role of the corneal nerve in ocular surface health and disease as a foundation for enabling proper diagnosis and for selecting optimal treatment.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review the role of the corneal nerve in maintaining ocular surface homeostasis
  • Identify signs and symptoms of ocular disease related to corneal nerve dysfunction
  • Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
Course summary
Course opens: 
03/31/2023
Course expires: 
03/31/2028

Faculty

Stephen C. Pflugfelder, MD (Chair)
Professor of Ophthalmology
James and Margaret Elkins Chair
Baylor College of Medicine
Houston, Texas
Paul Karpecki, OD
Associate Professor
University of Pikeville School of Optometry
Pikeville, Kentucky
Director, Cornea and External Disease
Kentucky Eye Institute and Gaddie Eye Centers
Lexington, Kentucky
Melissa Toyos, MD
Partner and Director of Research
Toyos Clinic
Nashville, Tennessee

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Paul Karpecki, OD, is a consultant for AbbVie Inc, Akorn, Inc, Alcon, Aldeyra Therapeutics, Allergan, Ametek, Inc, Atlas Medical GmbH, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Bruno Vision, Cambium Medical Technologies, Dompé US, Inc, Gobiquity, Haag-Streit Group, Hilco Vision, Icare USA Inc, Imprimis Pharmaceuticals, Inc, Kala Pharmaceuticals, Kiora Pharmaceuticals, Inc, Konan Medical USA, Inc, Lentechs, Neurolens, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OCuSOFT Inc, Optase, Oyster Point Pharma, Inc, Rendia, Inc, RVL Pharmaceuticals, Inc, RxSIGHT, ScienceBased Health, Sentiss Pharma Pvt Ltd, Sight Sciences, StepWise Medical, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Visant Medical, Inc, Vital Tears LLC, and Zeiss; is an advisory board member of AstaReal, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, and Mallinckrodt; and has individual stocks or stock options in SilkTech Biopharmaceuticals.

Stephen C. Pflugfelder, MD, is a consultant for Allergan, Dompé US, Inc, Kala Pharmaceuticals, KOWA Pharmaceuticals America, Inc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Senju Pharmaceutical Co, Ltd; and is a contracted researcher for Dompé US, Inc, and Novartis Pharmaceuticals Corporation.

Melissa Toyos, MD, is a consultant for Bausch & Lomb Incorporated, Mallinckrodt, and RVL Pharmaceuticals, Inc; is a contracted researcher for Allysta Pharmaceuticals, Inc, Bausch & Lomb Incorporated, GreenLight Medicines, Lumenis, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau for Bausch & Lomb Incorporated, Mallinckrodt, and RVL Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Kurt Brubaker is a consultant for Aquinas Leadership Group, Lexitas Pharma Services, and 2e/Fire and Rain.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Dompé US, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.

©2023 MedEdicus LLC. 270.2

Please login or register to take this course.

This educational activity has expired. You will not be able to claim credit for this activity.